Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Net Income towards Common Stockholders (2016 - 2025)

iBio (IBIO) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with -$9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 106.07% to -$9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.7 million, a 83.93% decrease, with the full-year FY2025 number at -$18.4 million, down 94.18% from a year prior.
  • Net Income towards Common Stockholders was -$9.0 million for Q4 2025 at iBio, down from -$5.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $51000.0 in Q2 2021 to a low of -$23.0 million in Q4 2022.
  • A 5-year average of -$6.7 million and a median of -$5.0 million in 2025 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: skyrocketed 101.42% in 2021, then crashed 33539.22% in 2022.
  • iBio's Net Income towards Common Stockholders stood at -$15.7 million in 2021, then plummeted by 46.5% to -$23.0 million in 2022, then surged by 83.81% to -$3.7 million in 2023, then decreased by 17.22% to -$4.4 million in 2024, then tumbled by 106.07% to -$9.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Net Income towards Common Stockholders are -$9.0 million (Q4 2025), -$5.7 million (Q3 2025), and -$5.2 million (Q2 2025).